From the Globe and Mail:
A chemotherapy medicine that sells for $500 a vial is about to be marketed for double that amount due to changes in Canada's intellectual property rules that, unwittingly, will leave one pharmaceutical company with a monopoly on a long-established cancer drug.
The regulation changes will give Sanofi-aventis Canada eight years of market exclusivity over the colorectal cancer drug oxaliplatin as soon as the firm receives its licence from Health Canada to sell it - expected as early as next month.
That means that three other companies will have to stop selling versions of oxaliplatin to cancer centres, hospitals and patients at deep discounts. ...more
Monday, May 28, 2007
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment